




Clinical Outcomes – Sample Reports


Last updated: June 2021

Virta Performance Metrics




A1c Change

Population-wide decrease from starting A1c



Rx Change

Diabetes medication de-prescriptions by Virta physicians



Weight Loss

Population-wide decrease from starting weight



Patient Engagement

Direct feedback from your population

ABC Company patients remain engaged and satisfied with Virta

Enrolled Patients

XX

patients enrolled for 90 days¹

Patient Retention

XX%

% enrolled at day 90¹

Patient Net Promoter Score

XX

Reported in the last 90 days²
Scale of -100 to 100

Healthcare industry avg = 18

1. Patients who have completed > xx days in Virta treatment and registered before xx/xx/xx

2. Patients who provided an NPS score between xx/xx/xx through xx/xx/xx

ABC Company patients see positive outcomes at 90 days in Virta treatment

A1c Improvement

-X.X%

average A1c decrease
(from x.xx to x.xx%)
(n=xx)

Weight Loss

XX.X%

average body weight loss
(from xx lbs to xx lbs)

Medication Deprescription

XX.X%


(xx of xx)

percent of diabetes-specific
medications eliminated

Outcomes at xx days in clinic among patients enrolled > xx days at time of analysis (n=xx). Baseline HbA1c by laboratory measurement. When follow up HbA1c by laboratory measurement is not available, it is estimated using the last 120 days of historical patient data with a median error of 0.23. Diabetes-specific medications exclude metformin.



Patient Enrollment by Month




Patient Marketing Approach:

- Ongoing Virta sent emails to targeted members
- Virta was included in customer emails in Q1
- Testimonial mailer sent by Virta in Q2
- Mailer will include information about Virta in Q3

Improved Glycemic Control: 3x increase in ABC Company patients with sub-diabetic eA1c at xx days

Glycemic Control — Baseline vs. 90 Days of Treatment


■ <6.5%
 ■ 6.5–6.9%
 ■ 7.0–7.9%
 ■ ≥8.0%



Source: Virta internal EMR data at xx days for ABC Company patient population with type 2 diabetes enrolled >xx days at time of analysis (n=xx). Baseline HbA1c was laboratory measured. In the absence of follow up laboratory data, A1c is derived from a proprietary model which estimates A1c on each day based on baseline information and actual biomarker data recorded on each patient in the last 120 days. The median absolute error is 0.23. The median absolute error is 0.23. 1 patient (.65%) does not have a calculated estimated a1c on the given day of measurement. Results as of xx/xx/xx.



Insulin Dose Change: xx% less insulin prescribed to ABC Company patients xx days




ABC Company patients are saving money by extending refill frequency by 3x

- At baseline, a 1000-unit vial of insulin lasted 15 days. At day 365, the same vial lasts 42 days.
- ~10% of people with diabetes will always require some insulin because they are unable to produce their own

Source: Virta internal EMR data at xx days for ABC Company patient population enrolled >xx days at time of analysis. N=xx patients prescribed insulin at baseline. N=xx patients prescribed insulin at day xx. Among patients prescribed insulin, mean daily dosage was reduced 65 units/day to 41 units/day. Results as of xx/xx/xx.

BMI: xx% decrease in ABC Company patients with severe risk obesity at xx days

BMI — Baseline vs. 6 months of Treatment



Source: Virta internal EMR data at xx days for ABC Company patient population enrolled >xx days at time of analysis, n = xx. Fifteen patients (4.0%) did not log a weight during this time and are reflected as missing data. Weight was calculated as the average of all weights recorded between days 150 and 210 into treatment. Results as of xx/xx/xx





virta